Gamida Cell(GMDA) - 2023 Q3 - Earnings Call Transcript

Enrolled patients had relapsed or refractory lymphoma and were heavily pretreated with a median of six prior lines of therapy, including CAR T cell therapy in six patients and prior hematopoietic stem cell transplant in four patients. Financial income and expenses net were $16.5 million of income in the third quarter of 2023, compared to $741,000 in expenses in the same period of 2022. The $17.2 million change in financial income was primarily due to $14 million of income related to the valuation of warrant ...